Skip to main content
Premium Trial:

Request an Annual Quote

Cellectis Prices American Depositary Shares, Expects to Go Public Today

NEW YORK (GenomeWeb) – Gene editing firm Cellectis today priced its initial public offering of 5.5 million American Depositary Shares at $41.50 per ADS.  

Each ADS represents one share of the Paris-based firm. 

The company anticipates the ADSs to start trading on the Nasdaq Global Market today under ticker symbol "CLLS," and has granted the offering's underwriters a 30-day option to purchase up to an additional 825,000 shares. Bank of America Merrill Lynch, Jefferies, and Piper Jaffray are the joint book-running managers for the offering while Oppenheimer and Trout Capital are co-managers. 

Cellectis was founded in 1999 with technology licensed from the Institut Pasteur and focuses on developing immunotherapies based on engineered chimeric antigen receptor (CAR)-T cells. It offers products based on TAL effector nuclease technology, meganucleases, and pulse agile technology, according to the company's website. 

Cellectis operates three business divisions: bioresearch, cancer therapy, and plant sciences, which is based inMinnesota. In January the firm reached a deal with Ohio State University to develop and commercialize CAR technology targeting multiple myeloma cells. 

Last December it and the Two Blades Foundation signed a cross-licensing deal for their respective TALEN technologies.

The Scan

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.

Using Bees to Gain Insights into Urban Microbiomes

As bees buzz around, they pick up debris that provides insight into the metagenome of their surroundings, researchers report in Environmental Microbiome.

Age, Genetic Risk Tied to Blood Lipid Changes in New Study

A study appearing in JAMA Network Open suggests strategies to address high lipid levels should focus on individuals with high genetic risk and at specific ages.

Study Examines Insights Gained by Adjunct Trio RNA Sequencing in Complex Pediatric Disease Cases

Researchers in AJHG explore the diagnostic utility of adding parent-child RNA-seq to genome sequencing in dozens of families with complex, undiagnosed genetic disease.